VivoSeq
Oncology

Merkel Cell Skin Cancer

17

Pipeline Programs↗

0

Active Trials↗

13

Companies Involved↗

Merkel cell skin cancer is an emerging landscape with 17 programs across 13 companies. The most active players are Regeneron, Calithera Biosciences, Inc, Iovance Biotherapeutics, Inc.. 5 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 1C

Calithera Biosciences, Inc

1 program

Phase 1I

Iovance Biotherapeutics, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

17programs
Monoclonal antibody741%
Small molecule635%
Peptide212%
Protein / enzyme16%
RNA therapy16%

Modality classified for 100% of 17 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)